Skip to main content

CORRECTION article

Front. Pharmacol., 02 June 2023
Sec. Experimental Pharmacology and Drug Discovery
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1225522

Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor

This article is a correction to:

  1. Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor

    1. Read original article
Laura Grohs,Laura Grohs1,2Linhan ChengLinhan Cheng1Saskia Cnen,Saskia Cönen1,3Bassam G. HaddadBassam G. Haddad3Astrid Bülow,Astrid Bülow1,4Idil ToklucuIdil Toklucu5Lisa ErnstLisa Ernst6Jannis Krner,Jannis Körner5,7Günther SchmalzingGünther Schmalzing1Angelika LampertAngelika Lampert5Jan-Philipp Machtens,Jan-Philipp Machtens1,3Ralf Hausmann Ralf Hausmann1*
  • 1Institute of Clinical Pharmacology, RWTH Aachen University, Aachen, Germany
  • 2Department of Neurology, University Hospital, RWTH Aachen University, Aachen, Germany
  • 3Molecular and Cellular Physiology (IBI-1), Institute of Biological Information Processing (IBI), Jülich, Germany
  • 4Department of Plastic Surgery, Hand and Burn Surgery, University Hospital RWTH Aachen, Aachen, Germany
  • 5Institute of Physiology (Neurophysiology), RWTH Aachen University, Aachen, Germany
  • 6Institute for Laboratory Animal Science and Experimental Surgery, RWTH Aachen University, Aachen, Germany
  • 7Department of Anesthesiology, University Hospital RWTH Aachen, Aachen, Germany

A Corrigendum on
Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor

by Grohs L, Cheng L, Cönen S, Haddad BG, Bülow A, Toklucu I, Ernst L, Körner J, Schmalzing G, Lampert A, Machtens J-P and Hausmann R (2023). Front. Pharmacol. 14:1120360. doi: 10.3389/fphar.2023.1120360

Incorrect Supplementary Material

In the published article, there was an error in Supplementary Material PDF file.

1.) In the Supplementary Material PDF file the heading is incorrect. Instead of “Allosteric” it should be “Competitive” as it is also stated in the title of the main article. The correct heading of the Supplementary Material PDF file is “Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor.”

2.) One author’s name has changed from Astrid Obrecht to Astrid Bülow. In addition, one authors is missing in the heading of the Supplementary Material PDF file. The author list should be Laura Grohs1,2, Linhan Cheng1, Saskia Cönen1,3, Bassam G. Haddad3, Astrid Bülow1,4, Idil Toklucu5, Lisa Ernst6, Jannis Körner5,7, Günther Schmalzing1, Angelika Lampert5, Jan-Philipp Machtens1,3 and Ralf Hausmann1*

The correct material statement appears below.

Heading of Supplementary Material PDF file:

“Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor.”

Laura Grohs1,2, Linhan Cheng1, Saskia Cönen1,3, Bassam G. Haddad3, Astrid Bülow1,4, Idil Toklucu5, Lisa Ernst6, Jannis Körner5,7, Günther Schmalzing1, Angelika Lampert5, Jan-Philipp Machtens1,3 and Ralf Hausmann1*

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: P2X3 receptor, nociception, chronic pain, non-steroidal anti-inflammatory drugs (NSAIDs), competitive antagonist, drug screening

Citation: Grohs L, Cheng L, Cönen S, Haddad BG, Bülow A, Toklucu I, Ernst L, Körner J, Schmalzing G, Lampert A, Machtens J-P and Hausmann R (2023) Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor. Front. Pharmacol. 14:1225522. doi: 10.3389/fphar.2023.1225522

Received: 19 May 2023; Accepted: 22 May 2023;
Published: 02 June 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Grohs, Cheng, Cönen, Haddad, Bülow, Toklucu, Ernst, Körner, Schmalzing, Lampert, Machtens and Hausmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ralf Hausmann, cmhhdXNtYW5uQHVrYWFjaGVuLmRl

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.